Eisai Announces Launch of Zonegran(R)(zonisamide), Treatment For Epilepsy In the U.K. and Germany
Eisai Co., Ltd. announced that its U.K. subsidiary Eisai Ltd. and German subsidiary Eisai GmbH have begun marketing Zonegran(R) hard capsules (zonisamide), an anti-epileptic drug for the adjunctive therapy of partial seizures in adults, in the U.K. and Germany, respectively. U.K and Germany are the first countries in which Zonegran(R) will be marketed in Europe. In the future, Eisai aims at marketing Zonegran(R) across Europe.
Major characteristics of Zonegran(R) are that it has multiple mechanisms of action giving it a broad spectrum of pharmacological activity and its drug-drug interactions with other anti-epileptic drugs are minimal. Zonegran(R) was approved and launched in March 2000 in the U.S. for adjunctive therapy in the treatment of partial seizures in adults with epilepsy. Eisai Inc., a subsidiary in the U.S., has been marketing the product since the end of April 2004.
Through marketing of Zonegran(R), Eisai will aim to strengthen its neurology product pipeline in Europe in order to fulfil patients' needs and contribute to further improve benefits with drug treatment.
Weitere News aus dem Ressort Forschung & Entwicklung
